Literature DB >> 18396446

Primary mucosal melanoma of the head and neck. Comparison of clinical presentation and histopathologic features of oral and sinonasal melanoma.

Nicolas McLean1, Mourad Tighiouart, Susan Muller.   

Abstract

We reviewed all cases of head and neck mucosal melanomas (HNMM) treated at Emory University and affiliated hospitals during a 20 year period and evaluate overall survival, recurrences and efficacy of treatment. Comparisons were made between sinonasal melanoma (SNM) and oral cavity melanoma (OCM) including clinical features, histopathologic features, treatment, and clinical outcomes. We analyzed pathologic features and clinical outcomes of 22 cases of primary SNM and eight cases of OCM treated at Emory University Hospital between 1986 and 2006. Sixteen patients were stage I (53%), nine patients were stage II (30%) and five patients were stage III (17%). Mean age was 67.5 years with a range from 32 to 85 years. Sixty percent were men and 92% were white. The average follow-up time was 22.1 months and the median was 15.5 months. The average delay between onset of symptoms and diagnosis was 5.6 months. Patients with SNM had a lower incidence of nodal metastasis at initial presentation when compared with OCM (22% vs. 50%) (p<.08). Surgical resection was the primary treatment and was performed in 27/30 patients (90%). Two patients with SNM and 1 patient with OCM, because of advanced stage at diagnosis had no treatment. Radiation was used in 50% (15) of the patients and radiation as postoperative therapy was administered to 44.8% (13) of the patients. The combination of surgery, radiation and adjuvant therapy was administered to 39.2% (11/2 8) of the patients. The recurrence rate at the time of closing this study was 43.3% (13 patients) with a mean time for development of recurrences of 13.1 months. Twenty-five patients (83%) died during the course of this study. Nineteen deaths (82%) corresponded to patients with SNM and six deaths (75%) to patients with OCM. The overall survival mean time was 21 months (median 12.5) with a range between 1 and 143 months. The 1, 2, 3, and 5 year survival rate for this study was 53.3%, 40%, 15% and 10%, respectively. The oral cavity was the location for the two patients still alive after 5 years. Although survival time correlated with Stage, particularly Stage 1, this was not statistically significant. Survival time did not correlate with surgery or adjuvant therapy. Statistically significant differences were noted between the pathologic features of OCM and SNM. These significant pathologic differences did not correlate with disease specific survival: OCM and SNM (median survival, 17 months vs. 12 months). Mucosal melanoma of the head and neck is a rare entity. Unfortunately, most patients present with advanced local disease. Local, regional recurrences and distant metastasis still occur despite the implementation of aggressive treatment, including surgery, radiation and adjuvant therapy. Despite significant pathologic differences between SNM and OCM, no survival advantage was seen.

Entities:  

Mesh:

Year:  2008        PMID: 18396446     DOI: 10.1016/j.oraloncology.2008.01.014

Source DB:  PubMed          Journal:  Oral Oncol        ISSN: 1368-8375            Impact factor:   5.337


  27 in total

1.  [Localized, irregular pigmentation of the maxillary gingiva].

Authors:  R K Rahimi-Nedjat; K Sagheb; A Tuettenberg; C Renné; C Walter
Journal:  Hautarzt       Date:  2016-04       Impact factor: 0.751

2.  Melanoma of the Oral Cavity: an Analysis of 46 New Cases with Emphasis on Clinical and Histopathologic Characteristics.

Authors:  Molly Housley Smith; Indraneel Bhattacharyya; Donald M Cohen; Nadim M Islam; Sarah G Fitzpatrick; Lindsay J Montague; Douglas D Damm; Craig B Fowler
Journal:  Head Neck Pathol       Date:  2016-01-11

3.  Association of Surgical Approach and Margin Status With Oncologic Outcomes Following Gross Total Resection for Sinonasal Melanoma.

Authors:  Zafar Sayed; Jocelyn C Migliacci; Jennifer R Cracchiolo; Christopher A Barker; Nancy Y Lee; Sean M McBride; Viviane S Tabar; Ian Ganly; Snehal G Patel; Luc T Morris; Benjamin R Roman; Alexander N Shoushtari; Marc A Cohen
Journal:  JAMA Otolaryngol Head Neck Surg       Date:  2017-12-01       Impact factor: 6.223

4.  Cisplatin and 4-hexylresorcinol synergise to decrease metastasis and increase survival rate in an oral mucosal melanoma xenograft model: a preliminary study.

Authors:  Sang-Woon Lee; Seong-Gon Kim; Young-Wook Park; Haeyong Kweon; Jwa-Young Kim; Horatiu Rotaru
Journal:  Tumour Biol       Date:  2013-02-15

5.  Clinical analysis of 29 cases of nasal mucosal malignant melanoma.

Authors:  Huanxin Yu; Gang Liu
Journal:  Oncol Lett       Date:  2015-05-25       Impact factor: 2.967

6.  Heparanase expression correlates with poor survival in oral mucosal melanoma.

Authors:  Xin Wang; Weiwei Wen; Heming Wu; Yi Chen; Guoxin Ren; Wei Guo
Journal:  Med Oncol       Date:  2013-06-21       Impact factor: 3.064

7.  Primary mucosal melanoma of the sinonasal tract: a clinicopathologic and immunohistochemical study of thirty-two cases.

Authors:  Mark C Mochel; Lyn M Duncan; Adriano Piris; Stefan Kraft
Journal:  Head Neck Pathol       Date:  2014-10-08

Review 8.  Primary mucosal melanomas: a comprehensive review.

Authors:  Marija Mihajlovic; Slobodan Vlajkovic; Predrag Jovanovic; Vladisav Stefanovic
Journal:  Int J Clin Exp Pathol       Date:  2012-10-01

9.  Spindle cell amelanotic lesion of the tongue: a diagnostic and therapeutic challenge.

Authors:  Vinay Kumar; Mridula Shukla; Umakanth Goud; Devendra Kumar Ravi; Mohan Kumar; Manoj Pandey
Journal:  Indian J Surg       Date:  2012-09-07       Impact factor: 0.656

10.  Multilocular sinonasal malignant melanoma: a poor prognostic subgroup?

Authors:  O Stanimirov Rossi; Domenic Vital; M B Soyka; T N Roth; G F Huber; D Holzmann
Journal:  Eur Arch Otorhinolaryngol       Date:  2014-05-29       Impact factor: 2.503

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.